The Vault Quality Suite will help Adare simplify its quality operations across its sites in the United States, France, and Italy.
Veeva Systems announced on Jan. 13, 2023 that Adare Pharma Solutions, a contract development and manufacturing (CDMO) with expertise in oral dosage forms, chose Veeva Vault Quality Suite to harmonize quality systems across the organization. This choice can help Adare streamline quality processes, work more effectively with partners and suppliers, and deliver greater visibility into operations to customers.
“As Adare expands its business, standardizing on the technology many of our customers use is a top priority to streamline collaboration,” said Audrey Butler, vice president, global head of quality at Adare Pharma Solutions, in a press release. “Veeva Vault Quality Suite will bring together our global teams on one platform for seamless processes and real-time data access that can help us improve how we work with clients and deliver differentiated services.”
The Vault Quality Suite will help Adare simplify its quality operations across its sites in the United States, France, and Italy. Further, Adare will use Veeva Vault QMS to manage all quality processes, Veeva Vault QualityDocs to control documents and ensure quality, and Veeva Vault Training to drive employee qualifications. This new collaboration helps Adare to manage content, data, and training in a single end-to-end quality system.
“We’re proud to partner with Adare Pharma Solutions to help support their goals of improving services for clients and delivering transformational medicines for patients,” said Ashley Wentworth, senior director, Veeva Vault Quality strategy, in a press release. “With the Veeva Vault Quality Suite, Adare will have a scalable cloud platform that can keep up with evolving industry and customer requirements.”
Source: Adare Pharma Solutions
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.